Nicolene Plaatjies

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis

K. C. Morris, Mohammed Salah Ibrahim, K. Y. Wong, 2022, medRxiv.

Economic Evaluation of Using Daily Prednisolone versus Placebo at the Time of an Upper Respiratory Tract Infection for the Management of Children with Steroid-Sensitive Nephrotic Syndrome: A Model-Based Analysis

D. Milford, M. Eisenhut, A. Webb, 2022, PharmacoEconomics - Open.

Assessing the feasibility of injectable growth-promoting therapy in Crohn’s disease

Ashley P Jones, P. Williamson, T. Jaki, 2016, Pilot and Feasibility Studies.

Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study

Sarah F. Griffee, Susan M. Kilroy, Philip Smith, 2022, The Lancet Gastroenterology & Hepatology.

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Steve B Jones, K. Y. Wong, Chamil H. Hettiarachchi, 2021, Lancet.

Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab

Susan M. Kilroy, C. Lees, T. Ahmad, 2022, Nature Communications.